ArticlePain practice : the official journal of World Institute of Pain2026
Elevated Serum Soluble CD163 Indicates Macrophage Activation: A Potential Biomarker for Inflammation in Complex Regional Pain Syndrome?
Article in Pain practice : the official journal of World Institute of Pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral studies point towards the involvement of the immune system (especially the monocyte-macrophage system) in the pathophysiology of Complex Regional Pain Syndrome (CRPS), as shown by increased levels of the cytokines tumor necrosis factor (TNF)-α and interleukin (IL)-6. These cytokines are primarily released from pro-inflammatory M1 macrophages, but are difficult to measure in a clinical setting. Investigating the activity of tissue-resident macrophages by measuring soluble CD163 (sCD163) in serum is much more clinically applicable. sCD163 could potentially be a biomarker for determining inflammation in CRPS and would have direct consequences for the choice of therapy. The aim of this study is to investigate the tissue-resident macrophage activation in CRPS with sCD163 and explore the relationship between soluble IL-2R, which is a marker for T-cell activation, and sCD163.
methodsThe sCD163 levels were determined in this retrospective cohort study (MEC-2020-0716) in serum of CRPS patients (n = 22) and healthy controls (n = 27). ELISA kits were used to measure the levels of these markers. Data on demographics, pain scores (11-point Numeric Rating Scale: NRS), sIL-2R levels, signs and symptoms, and CRPS disease severity were also recorded.
resultsThe median serum sCD163 level was significantly higher in CRPS patients (CRPS 960.5 pg/mL [Q3-Q1: 1211.5-623.9] than in healthy controls 677.0 pg/mL [Q3-Q1: 828.0-469.5], p = 0.008). There was a statistically significant positive correlation between sCD163 and sIL-2R in the CRPS group (r
conclusionOur findings indicate that pro-inflammatory activation of tissue-resident macrophages and thus the monocyte-macrophage system is part of CRPS pathogenesis. The monocyte-macrophage system is an interesting new target for future research into the pathogenesis of CRPS, but also has potential for diagnosis, particularly for assessing the involvement of the immune system and choice of therapy in the individual CRPS patient. Measurement of the sCD163 could be a potential biomarker for inflammation in CRPS.
trial registrationThis retrospective cohort study was approved by the Medical Ethics Committee of the Erasmus MC University Medical Center (MEC-2020-0716).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.